Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock

NCT04963920 is registered in ClinicalTrials.gov with CytoSorbents Europe GmbH as lead sponsor.

NCT NCT04963920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04963920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock
Lead sponsor
CytoSorbents Europe GmbH
Phase
Not applicable
Overall status
Suspended
Start date
January 30, 2022
Completion date
May 31, 2027
Enrollment
260 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock